Article

Study finds no signs of toxicity with viscoanesthesia OVD

Lisbon, Portugal – A viscoanesthesia-type of an ophthalmic viscosurgical device (OVD) did not show toxic or cataractogenic effects in rabbit eyes, according to a four-part study conducted at the Moran Eye Institute at the University of Utah, Salt Lake City, United States.

Lisbon, Portugal – A viscoanesthesia-type of an ophthalmic viscosurgical device (OVD) did not show toxic or cataractogenic effects in rabbit eyes, according to a four-part study conducted at the Moran Eye Institute at the University of Utah, Salt Lake City, United States.

During a clinical research symposium on new biomaterials in anterior surgery, Lillian Werner, MD, presented the results of an in vivo study that evaluated the toxicity of a new OVD solution that combines sodium hyaluronate with lidocaine (VisThesia and VisThesia Light, Hyaltech Ltd.).

In comparing the sodium hyaluronate with lidocaine with Ophthalin Plus (IOLTech), a balanced salt solution, and 1% lidocaine, Dr. Werner and her colleagues at the Moran Eye Institute studied the potential of the OVD in not only eliminating surgical steps for intracameral injection of lidocaine during cataract or phakic IOL surgery, but whether it would prolong the anesthetic effect.

Dr. Werner reported that in the four parts of the study, toxicity to the cornea was tested by exposing the extracted rabbit corneas to the OVD solution. Then the endothelium of the eyes was stained with trypan blue and/or alizarin red. In one part of the study, the anterior chamber of 18 rabbit eyes was injected with the 0.1 ml of the OVD solution. After clinical follow-up of 15 to 90 days, the rabbits were sacrificed and their eyes were removed and processed for evaluation. Another part of the study looked at 29 rabbits, which underwent phacoemulsification and injected with 0.2 ml of the solution in the capsular bag.

Following the staining of the corneas, clinical examination, and histopathological analysis, Dr. Werner reported that the enucleated eyes showed no signs of toxicity to the corneal epithelium, ciliary body, or the retina. She also said there was no signs of cell necrosis, cell degeneration, or fibrous metaplasia.

Dr. Werner concluded that the study showed that the OVD could prolong the anesthetic effect of the lidocaine during either cataract surgery or phakic IOL implantation.

“We could not find in these studies, any toxicity of any intraocular structures of rabbit eyes,” Dr. Werner added. “There was no cataractogenic effect to the crystalline lens. There was no change in time for injection or removal of this viscoanesthesia in comparison to standard OVDs.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.